# Ticagrelore Alone Post PCI

Study · id `cardio:ct-nct06509893` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06509893](<https://clinicaltrials.gov/study/NCT06509893>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06509893

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5400 participants.

## Technical summary

Registry record NCT06509893. Randomized; triple masking; primary purpose treatment. Start 2024-08-01 (actual); primary completion 2025-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 5400 participants (planned count; ClinicalTrials.gov record NCT06509893, source copy `cardio:ctgov-nct06509893-2025-05-21`, retrieved 2026-10-26)
- Started: 2024-08-01 (actual) (ClinicalTrials.gov record NCT06509893, source copy `cardio:ctgov-nct06509893-2025-05-21`, retrieved 2026-10-26)
- Primary completion: 2025-12-01 (anticipated) (ClinicalTrials.gov record NCT06509893, source copy `cardio:ctgov-nct06509893-2025-05-21`, retrieved 2026-10-26)
- Completion: 2026-05-01 (anticipated) (ClinicalTrials.gov record NCT06509893, source copy `cardio:ctgov-nct06509893-2025-05-21`, retrieved 2026-10-26)
- Countries: Iran (ClinicalTrials.gov record NCT06509893, source copy `cardio:ctgov-nct06509893-2025-05-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06509893-2025-05-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ticagrelore Alone Post PCI
- Acronym: TICALONE
- Condition: Coronary Artery Disease
- Intervention (Drug): aspirin 80 mg and clopidogrel 75 mg daily
- Intervention (Drug): Ticagrelor 90 MG
- Lead sponsor: Shiraz University of Medical Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Shiraz University of Medical Sciences (`cardio:org-shiraz-university-of-medical-sciences`)

## Provenance

Content hash: c8acef048cfa7ac9ddc73e1e895ff1281d22c766e9cf852a8ecd7100a261c983
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
